3. Micra leadless pacemakerMedtronic has already started reaping the benefits from the FDA’s January approval of its Micra AV, which greatly expanding the number of people who could potentially benefit from leadless pacemaker technology.
The new Micra AV has the same size and shape as the original Micra system, but it has several additional internal atrial sensing algorithms that detect cardiac movement. The Micra AV is able to adjust pacing in the ventricle to coordinate with the atrium, enabling it to provide “AV synchronous” pacing therapy to people with atrioventricular block. People with AV block have previously needed a dual-chamber pacemaker, even though only one of the two leads in system provided heart stimulation.
“Micra, our leadless pacemaker grew in the low-40s globally, and approximately 60% in the U.S.,” Martha said.
When it comes to high-power implantable heart devices, Medtronic is seeing success with its next-gen Cobalt and Crome portfolio of implantable cardioverter-defibrillators (ICD) and cardiac resynchronization therapy-defibrillators (CRT-D).
“We launched these devices mid-quarter in the U.S. and we’re now working with a growing number of providers across the country, who have not implanted with Medtronic in years. Electrophysiologists are choosing Cobalt and Crome for their unique AF and heart failure therapeutic algorithms,” Martha said.